NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321

1.1 Dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta321

Site by Devopa
© Copyright 2019 NHS. All rights reserved.